Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus long-acting injectable risperidone effects on prolactin in hospitalized psychotic patients
IRCT20221003056082N1Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risperidone in Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by University of Social Welfare and Rehabilitation Sciences. Primary endpoint: Serum prolactin level. Started Feb 2023; status: completed.
02
Drugs
risperidone
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on IRCT20221003056082N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221003056082N1.